A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice

Part 1: Physician-Reported Outcomes to Characterize Physician Perspectives

The treatment preferences for participant profiles, an assessment of perceived disease burden on participants, an evaluation of barriers to optimal treatment, and treatment adherence and persistence will be collected from the main treating physician.

Time frame: Part 1: From 12 months prior to study enrollment

Part 1: Number of Participants Characterised by Their Demographics and Clinical Characteristics

Time frame: Part 1: From 12 months prior to study enrollment

Part 1: Number of Participants Characterised by Their Disease Burden, Health Status, Treatment Experiences

Time frame: Part 1: From 12 months prior to study enrollment

Part 1: Number of Participants Characterised by Medication Use

Time frame: Part 1: From 12 months prior to study enrollment

Part 1: Number of Participants Characterised by Their Lifestyle and Environmental Influences

Time frame: Part 1: From 12 months prior to study enrollment

Part 1: Change From Baseline in Patient Global Impression of Severity (PGIS) Score

The PGIS is a single question asking the participant to rate their severity and symptom control. The PGIS is a 5-point ordinal scale ranging from 1 (No symptoms) to 5 (Very severe symptoms). Higher scores indicate greater symptom severity.

Time frame: Part 1: From 12 months prior to study enrollment

Part 1: Number of Participants Characterised by Inhaled and Systemic Corticosteroid Use

Time frame: Part 1: From 12 months prior to study enrollment

Part 1: Number of Participants Characterised by Healthcare Resource Utilization (HCRU)

Time frame: Part 1: From 12 months prior to study enrollment

Part 1: Change From Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) Score

The WPAI-Asthma is an Asthma-specific, patient-reported measure of work absenteeism, work presenteeism (reduced productivity while working due to illness), total work productivity loss (absenteeism plus presenteeism), and overall activity impairment over the prior 7 days. The WPAI-Asthma questionnaire score represents the percentage of impairment, from 0 to 100%. Higher scores represent greater impairment and less productivity.

Time frame: Part 1: From 12 months prior to study enrollment

Part 2: Descriptive Characterization Including Sociodemographics and Disease Characteristics and Treatment History.

Time frame: Part 2: At baseline

Part 2: Annualized Exacerbation Rates at Week 52 and 104

Time frame: Part 2: At Weeks 52 and 104

Part 2: Changes From Baseline to Week 104 in Pre and Post Bronchodilator Forced Expiratory Volume in 1 Second (FEV1)

FEV1 will be measured in Liters. Change from baseline: mean of (value of observed FEV1 at treatment duration minus baseline value).

Time frame: Part 2: From baseline to week 52 and week 104

Part 2: Number of Participants With Significant Changes in Asthma Treatment Patterns at Week 52 and Week 104

Changes in treatment patterns including use of SCS, ICS, other asthma therapies, and rescue medication. Treatment escalation (for example \[e.g.\], ICS dose changes, addition of asthma therapies, or biologic prescription), treatment adherence, and treatment persistence will be assessed from baseline to Week 52 and Week 104 in participants with Asthma.

Time frame: Part 2: From baseline to week 52 and week 104

Part 2: Changes in Physician Global Assessment of Asthma Severity, Symptom Control and Comorbidities (PhGIS)

Asthma severity, asthma control, and comorbidity will be assessed using three global impression of severity items: PhGIS - asthma severity. PhGIS - asthma control, and PhGIS - comorbidity.

Time frame: Part 2: From baseline to week 52 and week 104

Part 2: Number of Participants With Comorbidities and Burden of Comorbidities Based on the Participant Survey Using the PGIS scale

The PGIS is a single question asking the participant to rate their severity and symptom control. The PGIS is a 5-point ordinal scale ranging from 1 (No symptoms) to 5 (Very severe symptoms). Higher scores indicate greater symptom severity.

Time frame: Part 2: At Weeks 52 and 104

Part 2: Number of Participants With Comorbidities and Burden of Comorbidities Based on the Physician Survey Using the PhGIS Scale

Asthma severity, asthma control, and comorbidity will be assessed using three global impression of severity items: PhGIS - asthma severity. PhGIS - asthma control, and PhGIS - comorbidity.

Time frame: Part 2: At Weeks 52 and 104

Part 2: Number of Participants Analyzed for Changes in Inhaled and Systemic Corticosteroid Burden

Time frame: Part 2: From baseline up to week 104

Part 2: Changes in Physician-reported HCRU (Hospitalizations, Outpatient and Emergency Visits)

Data about HCRU associated with medical encounters will be collected by physicians from medical records. The data collected will include setting, department, type of specialist, the reasons and duration of hospitalizations, outpatient and emergency room (ER) visits.

Time frame: Part 2: From baseline to week 52 and week 104

Part 2: Changes in Patient-Reported Outcomes to Characterize Disease Evolution

PROs used will include but not limited to ACQ-5, mini-AQLQ. ACQ-5 questions are scored on a 6-point scale (0 = good control, 6 = poor control), Mean of the five responses is the overall score. Scores are then classified into three groups as having well-controlled asthma (score \<= 0.75); partially controlled asthma (score 0.75-1.5), or not well controlled asthma (score \>1.5). AQLQ includes 32 items, The mini-AQLQ is a reduced version of the AQLQ which includes 15 items. The questions correspond to 4 dimensions of health: symptoms (5 items), limitation of usual activities (4 items), emotional function (3 items) and environmental stimuli (3 items). The response options for each item are on an equidistant scale of 7 points, where 1 corresponds to the maximum disability and 7 to the absence of disability.

Time frame: Part 2: At Weeks 52 and 104

Part 2: Changes in Participant Survey Response

Participant survey collecting demographics, clinical characteristics, disease burden, health status, treatment experiences, medication use and burden, work and school impacts, lifestyle and environmental influences, impacts on daily life, PGIS for each comorbidity and burden of comorbidities, inhaled and systemic corticosteroid burden (frequency of use, routes of administration, treatment satisfaction), and HCRU office visits, hospitalizations, outpatient and emergency visits will be collected from medical records.

Time frame: Part 2: From baseline to week 52 and week 104

Part 2: Changes in Biomarker Level

Time frame: Part 2: At Weeks 52 and 104